Disc Medicine Reports Q3 2026 Financial Results and Operational Progress

Disc Medicine reported a narrower net loss in Q3 2026 than a year earlier. Its APOLLO trial met both co-primary endpoints, supporting a planned resubmission of the bitopertin NDA by the end of 2026. An October capital offering extended the company’s expected funding runway into 2030, and Disc Medicine reported progress on its selcodebart and DISC-3405 programs.